2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era– Tweetorial #6 Evaluation (ID: i777-28) Survey

Question Title

* 2. How many patients with MS do you manage per week? 

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 3. Please select the option that best describes your practice setting.

Academic medical center

Community medical center

VA, DOD, or other government

Managed care

Research

Pharmaceutical industry

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with MS in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity? 

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Knowledge of current criteria for the diagnosis of MS

Knowledge of factors that predict poor prognosis in patients with MS

Knowledge of clinical trial evidence regarding the safety and efficacy of current and emerging DMTs for the treatment of MS

An understanding of the potential for reduction of disability accumulation and disease progression with early DMT

An understanding of how to tailor treatment plans based upon individual patient characteristics and preferences

An awareness of current recommendations for MS management during the COVID-19 era

Question Title

* 8. What barriers do you see to making changes in your practice? Please select all that apply. 

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

After participating in today’s activity, I am now better able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Recognize the importance of early diagnosis & treatment in reducing disability progression among patients with MS	Recognize the importance of early diagnosis & treatment in reducing disability progression among patients with MS Strongly agree	Recognize the importance of early diagnosis & treatment in reducing disability progression among patients with MS Agree	Recognize the importance of early diagnosis & treatment in reducing disability progression among patients with MS Neutral	Recognize the importance of early diagnosis & treatment in reducing disability progression among patients with MS Disagree	Recognize the importance of early diagnosis & treatment in reducing disability progression among patients with MS Strongly disagree
Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, & patient preference	Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, & patient preference Strongly agree	Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, & patient preference Agree	Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, & patient preference Neutral	Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, & patient preference Disagree	Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, & patient preference Strongly disagree
Evaluate the latest data on the efficacy, safety, & dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS	Evaluate the latest data on the efficacy, safety, & dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Strongly agree	Evaluate the latest data on the efficacy, safety, & dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Agree	Evaluate the latest data on the efficacy, safety, & dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Neutral	Evaluate the latest data on the efficacy, safety, & dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Disagree	Evaluate the latest data on the efficacy, safety, & dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS Strongly disagree

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

Aaron Boster, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the Material	Presented the Material Strongly agree	Presented the Material Agree	Presented the Material Neutral	Presented the Material Disagree	Presented the Material Strongly disagree
Avoided Commercial Bias	Avoided Commercial Bias Strongly agree	Avoided Commercial Bias Agree	Avoided Commercial Bias Neutral	Avoided Commercial Bias Disagree	Avoided Commercial Bias Strongly disagree

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

Barry A. Singer, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the Material	Presented the Material Strongly agree	Presented the Material Agree	Presented the Material Neutral	Presented the Material Disagree	Presented the Material Strongly disagree
Avoided Commercial Bias	Avoided Commercial Bias Strongly agree	Avoided Commercial Bias Agree	Avoided Commercial Bias Neutral	Avoided Commercial Bias Disagree	Avoided Commercial Bias Strongly disagree

Question Title

* 12. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era– Tweetorial #6 Evaluation (ID: i777-28)

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with MS do you manage per week?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with MS in your practice?

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 8. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

After participating in today’s activity, I am now better able to:

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

Aaron Boster, MD, effectively:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

Barry A. Singer, MD, effectively:

Question Title

* 12. The content presented:

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

Question Title

* 15. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with MS do you manage per week?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with MS in your practice?

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 8. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree After participating in today’s activity, I am now better able to:

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree Aaron Boster, MD, effectively:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree Barry A. Singer, MD, effectively:

Question Title

* 12. The content presented:

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

Question Title

* 15. If you indicated that you perceived commercial bias or influence, please describe:

* 1. How many years have you been in practice? 

* 2. How many patients with MS do you manage per week? 

* 5. How committed are you to making changes in your practice based on your participation in this activity? 

* 8. What barriers do you see to making changes in your practice? Please select all that apply. 

* 9. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

After participating in today’s activity, I am now better able to:

* 10. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

Aaron Boster, MD, effectively:

* 11. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

Barry A. Singer, MD, effectively: